Clinical Trial Update: Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating monthly pasireotide for efficacy and safety in Cushing's disease has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Disease

Drugs mentioned

• SIGNIFOR (PASIREOTIDE)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cushing's Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-04-11